Please ensure Javascript is enabled for purposes of website accessibility

Why 22nd Century Group, Inc. Are Climbing Higher Today

By Cory Renauer - Oct 6, 2017 at 4:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Long-awaited, clinical-trial results suggest the company's low-nicotine tobacco helps smokers quit.

What happened

Shares of plant biotechnology company, 22nd Century Group, Inc. (XXII 0.00%) hit a new 52-week high Friday, gaining 12.1% as of 3:52 p.m. EDT. Recently presented results from a big clinical trial suggest the company's patented tobacco technology helps smokers drop the habit.

So what

Although the details of the 1,250-patient study are still under peer review, preliminary results from the University of Pittsburgh sponsored study bode well for 22nd Century Group. The lead investigator stated that smokers whose nicotine intake was immediately reduced by switching to cigarettes filled with the company's very low nicotine (VLN) tobacco had a better chance of rapidly quitting than smokers who were gradually weaned off the addictive substance.

Happy person with raised arms in front of an upward sloping chart.

Image source: Getty Images.

Friday's announcement comes at a good time for 22nd Century Group. Earlier this year, recently appointed Food and Drug Administration (FDA) Commissioner Scott Gottlieb promised to finally flex the regulatory muscle congress enacted about eight years ago. 22nd Century Group claims it's the only company capable of supplying America's $130 billion industry with VLN tobacco.

Now what

It's important to note, 22nd Century Group didn't release any data from the study. We don't know how many patients given VLN cigarettes ceased smoking permanently, or if there was a statistically significant difference between the groups.

While Friday's announcement does little to improve the company's outlook, becoming the U.S. tobacco industry's exclusive supplier of cigarette tobacco would expand the company's recent $357 million market cap many times over. The FDA hasn't given any timing details regarding a possible VLN cigarette mandate, and none of the industry heavyweights have signed any big contracts yet. Until they do, investors better stay braced for volatility.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

22nd Century Group, Inc. Stock Quote
22nd Century Group, Inc.
XXII
$2.13 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.